14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $4.18 $5.34 Wednesday, 24th Apr 2024 BCRX stock ended at $4.21. This is 3.88% less than the trading day before Tuesday, 23rd Apr 2024. During the day the stock fluctuated 5.74% from a day low at $4.18 to a day high of $4.42.
90 days $4.18 $6.35
52 weeks $4.18 $9.07

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Apr 24, 2024 $4.37 $4.42 $4.18 $4.21 3 808 518
Apr 23, 2024 $4.44 $4.63 $4.37 $4.38 4 233 738
Apr 22, 2024 $4.43 $4.57 $4.39 $4.41 2 183 024
Apr 19, 2024 $4.50 $4.59 $4.27 $4.43 4 691 978
Apr 18, 2024 $4.60 $4.71 $4.49 $4.50 2 956 572
Apr 17, 2024 $4.65 $4.79 $4.57 $4.58 3 914 121
Apr 16, 2024 $4.61 $4.72 $4.54 $4.61 1 928 439
Apr 15, 2024 $4.78 $4.79 $4.59 $4.67 2 419 468
Apr 12, 2024 $5.10 $5.16 $4.70 $4.77 4 525 350
Apr 11, 2024 $4.93 $5.12 $4.82 $5.10 3 188 600
Apr 10, 2024 $4.64 $4.91 $4.56 $4.87 2 914 995
Apr 09, 2024 $4.61 $4.88 $4.61 $4.80 1 956 309
Apr 08, 2024 $4.62 $4.67 $4.54 $4.61 1 557 303
Apr 05, 2024 $4.56 $4.66 $4.45 $4.60 1 765 454
Apr 04, 2024 $4.76 $4.84 $4.58 $4.60 2 681 785
Apr 03, 2024 $4.71 $4.77 $4.60 $4.73 2 974 161
Apr 02, 2024 $4.95 $5.01 $4.68 $4.69 3 668 727
Apr 01, 2024 $5.04 $5.09 $4.91 $5.05 4 752 465
Mar 28, 2024 $5.20 $5.34 $5.06 $5.08 3 475 501
Mar 27, 2024 $5.04 $5.21 $4.97 $5.15 2 517 428
Mar 26, 2024 $5.01 $5.15 $4.99 $5.01 2 974 037
Mar 25, 2024 $5.00 $5.08 $4.84 $4.91 2 785 843
Mar 22, 2024 $5.51 $5.51 $5.01 $5.01 3 230 681
Mar 21, 2024 $5.50 $5.86 $5.47 $5.49 2 511 666
Mar 20, 2024 $5.31 $5.49 $5.17 $5.47 3 176 034
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT